Согласованная позиция экспертов Евразийской ассоциации терапевтов по некоторым новым механизмам патогенеза COVID-19: фокус на гемостаз, вопросы гемотрансфузии и систему транспорта газов крови

В статье обсуждаются вопросы патогенеза и лечения COVID-19. Представлены современные данные о нарушениях системы гемостаза у пациентов с COVID-19 и клинические рекомендации по профилактике тромбозов и эмболий у пациентов, инфицированных SARS-CoV-2. Подробно обсуждено предположение, выдвинутое китайскими врачами, о новом звене в патогенезе COVID-19, а именно, о влиянии вируса SARS-CoV-2 на бета-цепь гемоглобина и формирование комплекса с порфирином, что приводит к вытеснению иона железа. Тем самым гемоглобин лишается возможности осуществлять транспорт кислорода, что усугубляет гипоксию и ухудшает прогноз. В статье представлены данные о правилах безопасности гемотрансфузий на фоне пандемии COVID-19.

1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507–13. DOI: 10.1016/S0140-6736(20)30211-7

2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5

3. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. 2020;18(4):844–7. DOI: 10.1111/jth.14768

4. Xie Y, Wang X, Yang P, Zhang S. COVID-19 Complicated by Acute Pulmonary Embolism. Radiology: Cardiothoracic Imaging. 2020;2(2):e200067. DOI: 10.1148/ryct.2020200067

5. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? European Heart Journal. 2020;ehaa254. [Epub ahead of print]. DOI: 10.1093/eurheartj/ehaa254

6. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerging Microbes & Infections. 2020;9(1):687–90. DOI: 10.1080/22221751.2020.1741327

7. Schmitt FCF, Manolov V, Morgenstern J, Fleming T, Heitmeier S, Uhle F et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Annals of Intensive Care. 2019;9(1):19. DOI: 10.1186/s13613-019-0499-6

8. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. Journal of Thrombosis and Haemostasis. 2020;jth.14810. [Epub ahead of print]. DOI: 10.1111/jth.14810

9. Fung S-Y, Yuen K-S, Ye Z-W, Chan C-P, Jin D-Y. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerging Microbes & Infections. 2020;9(1):558–70. DOI: 10.1080/22221751.2020.1736644

10. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia - a review. Critical Care Medicine. 2006;34(3):871–7. DOI: 10.1097/01.CCM.0000201882.23917.B8

11. Evans CE. Hypoxia and HIF activation as a possible link between sepsis and thrombosis. Thrombosis Journal. 2019;17(1):16. DOI: 10.1186/s12959-019-0205-9

12. Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV-2 and non-SARSCoV-2. Journal of Thrombosis and Thrombolysis. 2020; [Epub ahead of print]. DOI: 10.1007/s11239-020-02105-8

13. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020; [Epub ahead of print]. DOI: 10.1001/jamacardio.2020.1017

14. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation. 2020;137244. [Epub ahead of print]. DOI: 10.1172/JCI137244

15. Ning Tang. Coagulation tests In COVID -19. Av. at: https://academy.isth.org/pdfviewer/web/viewer.html?file=https%3A//academy.isth.org/isth/2020/covid-19/document%3Fc_id%3D290512%26type%3Djournal_article.

16. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020; [Epub ahead of print]. DOI: 10.1056/NEJMoa2002032

17. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. DOI: 10.1001/jama.2020.1585

18. Министерство здравоохранения РФ. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 5 (08.04.2020). Москва. Доступно на: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/049/951/original/09042020_%D0%9C%D0%A0_COVID-19_v5.pdf?fbclid=IwAR0PLbz6taMKt4QZy7yXbdnYJFYhkr5pDOkLNFdKo-EyfkoPaPhy2syXNo

19. Hunt B, Retter A, McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. Av. at: https://thrombosisuk.org/downloads/T&H%20and%20COVID.pdf. 2020.

20. Moore HB, Barrett CD, Moore EE, McIntyre RC, Moore PK, Talmor DS et al. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?: Journal of Trauma and Acute Care Surgery. 2020; [Epub ahead of print]. DOI: 10.1097/TA.0000000000002694

21. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao S-Y. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. Journal of Thoracic Oncology. 2020;15(5):700–4. DOI: 10.1016/j.jtho.2020.02.010

22. Liu C, Ma Y, Su Z, Zhao R, Zhao X, Nie H-G et al. Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury. Frontiers in Immunology. 2018;9:1898. DOI: 10.3389/fimmu.2018.01898

23. Hardaway RM, Harke H, Tyroch AH, Williams CH, Vazquez Y, Krause GF. Treatment of severe acute respiratory distress syndrome: a final report on a phase I study. The American Surgeon. 2001;67(4):377–82. PMID: 11308009

24. The Liverpool Drug Interaction Group. Liverpool COVID-19 Interactions. Detailed recommendations for interactions with experimental COVID-19 therapies. 2020. [Internet] Available at: https://www.covid19-druginteractions.org/

25. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfusion Medicine Reviews. 2020; [Epub ahead of print]. DOI: 10.1016/j.tmrv.2020.02.003

26. Ng EKO, Ng P-C, Hon KLE, Cheng WTF, Hung ECW, Chan KCA et al. Serial Analysis of the Plasma Concentration of SARS Coronavirus RNA in Pediatric Patients with Severe Acute Respiratory Syndrome. Clinical Chemistry. 2003;49(12):2085–8. DOI: 10.1373/clinchem.2003.024588

27. Ng EKO, Hui DS, Chan KCA, Hung ECW, Chiu RWK, Lee N et al. Quantitative Analysis and Prognostic Implication of SARS Coronavirus RNA in the Plasma and Serum of Patients with Severe Acute Respiratory Syndrome. Clinical Chemistry. 2003;49(12):1976–80. DOI: 10.1373/clinchem.2003.024125

28. Grant PR, Garson JA, Tedder RS, Chan PKS, Tam JS, Sung JJY. Detection of SARS Coronavirus in Plasma by Real-Time RT-PCR. New England Journal of Medicine. 2003;349(25):2468–9. DOI: 10.1056/NEJM200312183492522

29. Drosten C, Günther S, Preiser W, van der Werf S, Brodt H-R, Becker S et al. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. New England Journal of Medicine. 2003;348(20):1967–76. DOI: 10.1056/NEJMoa030747

30. Corman VM, Albarrak AM, Omrani AS, Albarrak MM, Farah ME, Almasri M et al. Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection. Clinical Infectious Diseases. 2016;62(4):477–83. DOI: 10.1093/cid/civ951

31. World Health Organization. WHO Recommendations on SARS and Blood Safety. 2003. [Internet] Available at: https://www.who.int/csr/sars/guidelines/bloodsafety/en/

32. FDA. Revised recommendations for the assessment of donor suitability and blood product safety in cases of suspected severe acute respiratory syndrome (SARS) or exposure to SARS: guidance for industry. Av. at: https://www.fda.gov/media/124354/download. 2003.

33. Wang H, Mao Y, Ju L, Zhang J, Liu Z, Zhou X et al. Detection and Monitoring of SARS Coronavirus in the Plasma and Peripheral Blood Lymphocytes of Patients with Severe Acute Respiratory Syndrome. Clinical Chemistry. 2004;50(7):1237–40. DOI: 10.1373/clinchem.2004.031237

34. Li L, Wo J, Shao J, Zhu H, Wu N, Li M et al. SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients. Journal of Clinical Virology. 2003;28(3):239–44. DOI: 10.1016/S1386-6532(03)00195-1

35. Yilla M, Harcourt BH, Hickman CJ, McGrew M, Tamin A, Goldsmith CS et al. SARS-coronavirus replication in human peripheral monocytes/macrophages. Virus Research. 2005;107(1):93–101. DOI: 10.1016/j.virusres.2004.09.004

36. Law HKW, Cheung CY, Ng HY, Sia SF, Chan YO, Luk W et al. Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells. Blood. 2005;106(7):2366–74. DOI: 10.1182/blood-2004-10-4166

37. Schmidt M, Brixner V, Ruster B, Hourfar MK, Drosten C, Preiser W et al. NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions. Transfusion. 2004;44(4):470–5. DOI: 10.1111/j.1537-2995.2004.03269.x

38. Cheng PK, Wong DA, Tong LK, Ip S-M, Lo AC, Lau C-S et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. The Lancet. 2004;363(9422):1699–700. DOI: 10.1016/S0140-6736(04)16255-7

39. Hung IFN, Cheng VCC, Wu AKL, Tang BSF, Chan KH, Chu CM et al. Viral Loads in Clinical Specimens and SARS Manifestations. Emerging Infectious Diseases. 2004;10(9):1550–7. DOI: 10.3201/eid1009.040058

40. Poon TCW, Chan KCA, Ng P-C, Chiu RWK, Ang IL, Tong Y et al. Serial Analysis of Plasma Proteomic Signatures in Pediatric Patients with Severe Acute Respiratory Syndrome and Correlation with Viral Load. Clinical Chemistry. 2004;50(8):1452–5. DOI: 10.1373/clinchem.2004.035352

41. European Centre for Disease Prevention and Control. Rapid Risk Assessment: Outbreak of acute respiratory syndrome associated with a novel coronavirus, Wuhan, China; first update. Av. at: https://www.ecdc.europa.eu/sites/default/files/documents/Risk-assessmentpneumonia-Wuhan-China-22-Jan-2020.pdf. 2020.

42. American Association of Blood Banks. Update: impact of 2019 novel coronavirus and blood safety. Av. at: http://www.aabb.org/advocacy/regulatorygovernment/Documents/Impact-of-2019-Novel-Coronavirus-on-Blood-Donation.pdf. 2020.

43. Chinese Society of Blood Transfusion. Recommendations on blood collection and supply during the epidemic of novel coronavirus pneumonia in China, 1st edition [in Chinese]. Av. at: https://www.csbt.org.cn/plus/view.php?aid=16530. 2020.

44. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. International Journal of Antimicrobial Agents. 2020;105955. [Epub ahead of print]. DOI: 10.1016/j.ijantimicag.2020.105955

45. Luan J, Lu Y, Jin X, Zhang L. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARSCoV-2 infection. Biochemical and Biophysical Research Communications. 2020;526(1):165–9. DOI: 10.1016/j.bbrc.2020.03.047

46. Rizzo P, Vieceli Dalla Sega F, Fortini F, Marracino L, Rapezzi C, Ferrari R. COVID-19 in the heart and the lungs: could we ‘Notch’ the inflammatory storm? Basic Research in Cardiology. 2020;115(3):31. DOI: 10.1007/s00395-020-0791-5

47. Liu W, Li H. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. Av. at: https://chemrxiv.org/articles/COVID-19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173/7. 2020.

48. Wikipedia. Cross-sectional model of a coronavirus. Av. at: https://en.wikipedia.org/wiki/Coronavirus#/media/File:3D_medical_animation_coronavirus_structure.jpg.

49. Биохимия для студента. Гемоглобин – основной белок крови. Доступно на: https://biokhimija.ru/hemoglobin/obmen-gemoglobina.html

50. Li H, Liu S-M, Yu X-H, Tang S-L, Tang C-K. Coronavirus disease 2019 (COVID-19): current status and future perspectives. International Journal of Antimicrobial Agents. 2020;105951. [Epub ahead of print]. DOI: 10.1016/j.ijantimicag.2020.105951

51. Коронавирус 2019-nCoV и COVID-19. Доступно на: https://www.tehpodderzka.ru/2020/02/2019-nCoV.html [Internet] 2020.

52. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. 2020;24:91–8. DOI: 10.1016/j.jare.2020.03.005

53. IDSA Practice Guidelines. COVID-19 Guideline. Av. at: https://www.idsociety.org/practice-guideline/practice-guidelines/#/date_na_dt/DESC/0/+/. 2020.

54. CDC. Coronavirus Disease 2019 (COVID-19). 2020. [Internet] Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html

55. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? International Journal of Antimicrobial Agents. 2020;105938. [Epub ahead of print]. DOI: 10.1016/j.ijantimicag.2020.105938

56. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020; [Epub ahead of print]. DOI: 10.1001/jama.2020.4683

57. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269–71. DOI: 10.1038/s41422-020-0282-0